[1] 徐小元,丁惠国,李文刚,等. 肝硬化诊治指南. 临床肝胆病杂志, 2019, 35: 2408-2425.
[2] Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol, 2019, 71: 811-822.
[3] Angeli P, Rodríguez E, Piano S, et al. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut, 2015, 64: 1616-1622.
[4] Umemura T, Joshita S, Shibata S, et al. Renal impairment is associated with increased risk of mortality in patients with cirrhosis: a retrospective cohort study. Medicine, 2019, 98: e14475.
[5] Wong F, O′Leary JG, Reddy KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology, 2013, 145: 1280-1288.
[6] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南. 中华肝脏病杂志,2017,25:664-677.
[7] 史冬梅,项晓刚,王晓琳,等. 慢性肝病住院患者急性肾损伤的发病及预后相关因素分析. 肝脏, 2017, 22: 200-204.
[8] Wong F, O′Leary JG, Reddy KR, et al. Acute kidney injury in cirrhosis: baseline serum creatinine predicts patient outcomes. Am J Gastroenterol, 2017, 112: 1103-1110.
[9] Cullaro G, Park M, Lai JC. “Normal” creatinine levels predict persistent kidney injury and waitlist mortality in outpatients with cirrhosis. Hepatology, 2018, 68: 1953-1960.
[10] 王文娟,宋琦,丁惠国. 肝硬化患者急性肾损伤的临床特点及危险因素分析. 中华内科杂志, 2018, 57: 912-916.
[11] 曾龙驿,江玮. 重视糖尿病肾病发生机制的研究. 中华医学杂志, 2016, 96: 1313-1314.
[12] Barreto R, Fagundes C, Guevara M, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology, 2014, 59: 1505-1513.
[13] 吴小倩,苏菲. 失代偿期肝硬化患者急性肾损伤相关危险因素分析. 实用肝脏病杂志, 2014,17: 360-363.
[14] Solé C, Solà E, Huelin P, et al. Characterization of inflammatory response in hepatorenal syndrome: relationship with kidney outcome and survival. Liver Int, 2019, 39: 1246-1255.
[15] Wong F, Jepsen P, Watson H, et al. Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver Int, 2018, 38: 1785-1792.
[16] Chang Y, Qi X, Li Z, et al. Hepatorenal syndrome: insights into the mechanisms of intra-abdominal hypertension. Int J Clin Exp Pathol, 2013, 6: 2523-2528.
[17] Koola JD, Chen G, Malin BA, et al. A clinical risk prediction model to identify patients with hepatorenal syndrome at hospital admission. Int J Clin Pract, 2019, 73: e13393.
[18] Huelin P, Piano S, Solà E, et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure. Clin Gastroenterol Hepatol, 2017, 15: 438-445.
[19] Wong F. The evolving concept of acute kidney injury in patients with cirrhosis. Nat Rev Gastroenterol Hepatol, 2015, 12: 711-719.
[20] 李思阳,田英俊,李德春,等. 肝硬化患者失代偿期发生肝肾综合征的危险因素分析. 中国医师杂志, 2016, 18: 1723-1725.
[21] 抗乙型肝炎病毒核苷(酸)类似物不良反应管理专家委员会. 抗乙型肝炎病毒核苷(酸)类似物不良反应管理专家共识. 中国肝脏病杂志(电子版), 2016, 8: 10-14.
[22] Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology, 2014, 146: 1680-1690.
[23] Elia C, Graupera I, Barreto R, et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: a case-control study. J Hepatol, 2015, 63: 593-600.
[24] Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: “The Triple Whammy”. Nefrologia, 2015, 35: 197-206. |
